RFG Advisory LLC Makes New $968,000 Investment in The Chemours Company (NYSE:CC)

RFG Advisory LLC acquired a new position in shares of The Chemours Company (NYSE:CC - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 71,553 shares of the specialty chemicals company's stock, valued at approximately $968,000.

A number of other large investors have also recently bought and sold shares of CC. Strategic Financial Concepts LLC acquired a new stake in shares of Chemours in the 4th quarter valued at approximately $357,000. Entropy Technologies LP acquired a new stake in shares of Chemours in the 4th quarter valued at approximately $266,000. Sei Investments Co. boosted its stake in shares of Chemours by 779.5% in the 4th quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company's stock valued at $2,950,000 after purchasing an additional 154,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Chemours in the 4th quarter valued at approximately $515,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Chemours by 6.8% in the 4th quarter. Victory Capital Management Inc. now owns 110,311 shares of the specialty chemicals company's stock valued at $1,864,000 after purchasing an additional 7,052 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. UBS Group reduced their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group dropped their price objective on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Mizuho set a $15.00 price objective on shares of Chemours in a report on Tuesday, April 15th. Finally, Truist Financial dropped their price objective on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $17.22.

Chemours Stock Up 5.6%

Chemours stock opened at $10.63 on Friday. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $25.80. The firm has a 50 day moving average price of $11.24 and a two-hundred day moving average price of $15.43. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of 18.65 and a beta of 1.76.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the business posted $0.32 EPS. The firm's revenue for the quarter was up .4% compared to the same quarter last year. Equities analysts predict that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, June 16th. Shareholders of record on Monday, May 19th will be issued a dividend of $0.0875 per share. The ex-dividend date is Friday, May 16th. This represents a yield of 3.17%. Chemours's payout ratio is 175.00%.

Insiders Place Their Bets

In related news, CFO Shane Hostetter acquired 4,450 shares of the stock in a transaction dated Monday, May 19th. The stock was bought at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the purchase, the chief financial officer now directly owns 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Damian Gumpel acquired 7,822 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average price of $9.95 per share, with a total value of $77,828.90. Following the purchase, the insider now directly owns 131,701 shares in the company, valued at $1,310,424.95. This represents a 6.31% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 25,672 shares of company stock worth $251,573. 0.47% of the stock is currently owned by insiders.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.